Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA.
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Nat Chem Biol. 2022 Sep;18(9):934-941. doi: 10.1038/s41589-022-01019-1. Epub 2022 May 19.
The expansion of the target landscape of covalent inhibitors requires the engagement of nucleophiles beyond cysteine. Although the conserved catalytic lysine in protein kinases is an attractive candidate for a covalent approach, selectivity remains an obvious challenge. Moreover, few covalent inhibitors have been shown to engage the kinase catalytic lysine in animals. We hypothesized that reversible, lysine-targeted inhibitors could provide sustained kinase engagement in vivo, with selectivity driven in part by differences in residence time. By strategically linking benzaldehydes to a promiscuous kinase binding scaffold, we developed chemoproteomic probes that reversibly and covalently engage >200 protein kinases in cells and mice. Probe-kinase residence time was dramatically enhanced by a hydroxyl group ortho to the aldehyde. Remarkably, only a few kinases, including Aurora A, showed sustained, quasi-irreversible occupancy in vivo, the structural basis for which was revealed by X-ray crystallography. We anticipate broad application of salicylaldehyde-based probes to proteins that lack a druggable cysteine.
靶向共价抑制剂的靶标范围的扩大需要涉及半胱氨酸以外的亲核试剂。尽管蛋白激酶中保守的催化赖氨酸是共价方法的一个有吸引力的候选物,但选择性仍然是一个明显的挑战。此外,很少有共价抑制剂已被证明能在动物中与激酶的催化赖氨酸结合。我们假设可逆的、针对赖氨酸的抑制剂可以在体内提供持续的激酶结合,其选择性部分由停留时间的差异驱动。通过将苯甲醛策略性地连接到一个混杂的激酶结合支架上,我们开发了化学蛋白质组学探针,这些探针可以在细胞和小鼠中可逆且共价地结合超过 200 种蛋白激酶。醛基邻位的羟基极大地增强了探针-激酶的停留时间。值得注意的是,只有少数激酶,包括 Aurora A,在体内表现出持续的、准不可逆的占据,其结构基础通过 X 射线晶体学揭示。我们预计基于水杨醛的探针将广泛应用于缺乏可成药半胱氨酸的蛋白质。